NGeneBio Co (354200.KQ) Stock Price

NGeneBio Co Price

CLOSED
1,620.00KRW+100.00 (+6.37 %)
Market closed

Revenue has compounded at 47.6% per year over the past 7 years to 21.24 B KRW. NGeneBio Co's net margin stands at -26.1%, up from -117.7% several years earlier. The stock trades about 9% above its 52-week low.

NGeneBio Co stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of NGeneBio Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how NGeneBio Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing NGeneBio Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

NGeneBio Co Stock Price History
DateNGeneBio Co Price
7/31/20261,620.00 KRW
7/30/20261,520.00 KRW
7/29/20261,490.00 KRW
7/28/20261,745.00 KRW
7/27/20262,305.00 KRW
7/24/20262,585.00 KRW
7/23/20261,996.00 KRW
7/22/20262,370.00 KRW
7/21/20261,825.00 KRW
7/20/20261,654.00 KRW
7/16/20261,668.00 KRW
7/15/20261,710.00 KRW
7/14/20261,617.00 KRW
7/13/20261,666.00 KRW
7/10/20262,211.22 KRW
7/9/20262,211.22 KRW
7/8/20262,211.22 KRW
7/7/20262,211.22 KRW
7/6/20262,211.22 KRW
7/3/20262,211.22 KRW
7/2/20262,211.22 KRW
7/1/20262,211.22 KRW
6/30/20262,211.22 KRW
6/29/20262,211.22 KRW
6/26/20262,211.22 KRW
6/25/20262,211.22 KRW
6/24/20262,211.22 KRW
6/23/20262,211.22 KRW
6/22/20262,211.22 KRW
6/19/20262,376.24 KRW
6/18/20262,622.26 KRW
6/17/20262,670.27 KRW
6/16/20262,625.26 KRW
6/15/20262,643.26 KRW
6/12/20262,553.26 KRW
6/11/20262,676.27 KRW
6/10/20262,664.27 KRW
6/9/20262,847.28 KRW
6/8/20262,763.28 KRW
6/5/20262,976.30 KRW
6/4/20263,021.30 KRW
6/2/20263,036.30 KRW
6/1/20263,024.30 KRW
5/29/20263,210.32 KRW
5/28/20263,339.33 KRW
5/27/20263,300.33 KRW
5/26/20263,477.35 KRW
5/22/20263,504.35 KRW
5/21/20263,447.34 KRW
5/20/20263,624.36 KRW
5/19/20263,795.38 KRW
5/18/20263,771.38 KRW
5/15/20264,239.42 KRW
5/14/20263,750.38 KRW
5/13/20263,900.39 KRW
5/12/20263,705.37 KRW
5/11/20263,516.35 KRW
5/8/20263,357.34 KRW
5/7/20263,405.34 KRW
5/6/20263,456.35 KRW
5/4/20263,510.35 KRW
4/30/20263,477.35 KRW
4/29/20263,567.36 KRW
4/28/20263,675.37 KRW
4/27/20264,935.49 KRW
4/24/20265,061.51 KRW
4/23/20265,070.51 KRW
4/22/20265,178.52 KRW
4/21/20265,208.52 KRW
4/20/20265,370.54 KRW
4/17/20265,598.56 KRW
4/16/20265,361.54 KRW
4/15/20265,205.52 KRW
4/14/20265,103.51 KRW
4/13/20265,043.50 KRW
4/10/20265,031.50 KRW
4/9/20264,803.48 KRW
4/8/20264,974.50 KRW
4/7/20264,719.47 KRW
4/6/20264,725.47 KRW
4/3/20265,046.50 KRW
4/2/20264,983.50 KRW
4/1/20265,301.53 KRW
3/31/20265,139.51 KRW
3/30/20265,406.54 KRW
3/27/20265,490.55 KRW
3/26/20265,421.54 KRW
3/25/20265,610.56 KRW
3/24/20265,673.57 KRW
3/23/20265,640.56 KRW
3/20/20266,030.60 KRW
3/19/20266,135.61 KRW
3/18/20266,120.61 KRW
3/17/20266,180.62 KRW
3/16/20266,180.62 KRW
3/13/20266,165.62 KRW
3/12/20266,435.64 KRW
3/11/20266,240.62 KRW
3/10/20265,811.58 KRW
3/9/20265,862.59 KRW
3/6/20266,105.61 KRW
3/5/20266,180.62 KRW
3/4/20265,478.55 KRW
3/3/20266,000.60 KRW
2/27/20265,997.60 KRW
2/26/20265,982.60 KRW
2/25/20266,030.60 KRW
2/24/20265,910.59 KRW
2/23/20265,823.58 KRW
2/20/20266,120.61 KRW
2/19/20266,390.64 KRW
2/13/20266,750.68 KRW
2/12/20266,720.67 KRW
2/11/20266,585.66 KRW
2/10/20266,315.63 KRW
2/9/20267,155.72 KRW
2/6/20267,305.73 KRW
2/5/20266,930.69 KRW
2/4/20267,575.76 KRW
2/3/20267,620.76 KRW
2/2/20267,905.79 KRW
1/30/20266,090.61 KRW
1/29/20266,735.67 KRW
1/28/20266,045.60 KRW
1/27/20265,283.53 KRW
1/26/20265,100.51 KRW
1/23/20265,109.51 KRW
1/22/20265,256.53 KRW
1/21/20265,610.56 KRW
1/20/20265,856.59 KRW
1/19/20264,506.45 KRW
1/16/20264,197.42 KRW
1/15/20264,173.42 KRW
1/14/20264,161.42 KRW
1/13/20264,266.43 KRW
1/12/20264,296.43 KRW
1/9/20264,317.43 KRW
1/8/20264,380.44 KRW
1/7/20264,452.45 KRW
1/6/20264,440.44 KRW
1/5/20264,572.46 KRW
1/2/20264,422.44 KRW
12/30/20254,380.44 KRW
12/29/20254,434.44 KRW
12/26/20254,425.44 KRW
12/24/20254,545.45 KRW
12/23/20254,638.46 KRW
12/22/20254,695.47 KRW
12/19/20254,737.47 KRW
12/18/20254,701.47 KRW
12/17/20254,776.48 KRW
12/16/20254,773.48 KRW
12/15/20254,947.49 KRW
12/12/20255,100.51 KRW
12/11/20255,115.51 KRW
12/10/20255,103.51 KRW
12/9/20255,106.51 KRW
12/8/20255,109.51 KRW
12/5/20255,112.51 KRW
12/4/20255,103.51 KRW
12/3/20255,175.52 KRW
12/2/20255,160.52 KRW
12/1/20255,097.51 KRW
11/28/20255,007.50 KRW
11/27/20254,911.49 KRW
11/26/20254,860.49 KRW
11/25/20254,953.50 KRW
11/24/20255,109.51 KRW
11/21/20255,037.50 KRW
11/20/20255,145.51 KRW
11/19/20255,142.51 KRW
11/18/20254,977.50 KRW
11/17/20255,112.51 KRW
11/14/20254,800.48 KRW
11/13/20254,851.49 KRW
11/12/20254,500.45 KRW
11/11/20254,452.45 KRW
11/10/20254,263.43 KRW
11/7/20254,197.42 KRW
11/6/20254,233.42 KRW
11/5/20254,140.41 KRW
11/4/20254,188.42 KRW
11/3/20254,188.42 KRW
10/31/20254,440.44 KRW
10/30/20254,311.43 KRW
10/29/20254,668.47 KRW
10/28/20254,587.46 KRW
10/27/20254,515.45 KRW
10/24/20254,575.46 KRW
10/23/20254,767.48 KRW
10/22/20254,782.48 KRW
10/21/20254,728.47 KRW
10/20/20254,836.48 KRW
10/17/20254,839.48 KRW
10/16/20254,980.50 KRW
10/15/20255,097.51 KRW
10/14/20255,085.51 KRW
10/13/20254,995.50 KRW
10/10/20255,079.51 KRW
10/2/20255,094.51 KRW
10/1/20255,145.51 KRW
9/30/20255,214.52 KRW
9/29/20255,220.52 KRW
9/26/20255,154.52 KRW
9/25/20255,259.53 KRW
9/24/20255,340.53 KRW
9/23/20255,313.53 KRW
9/22/20255,379.54 KRW
9/18/20255,415.54 KRW
9/17/20255,391.54 KRW
9/16/20255,424.54 KRW
9/15/20255,412.54 KRW
9/12/20255,466.55 KRW
9/11/20255,481.55 KRW
9/10/20255,505.55 KRW
9/9/20255,436.54 KRW
9/8/20255,490.55 KRW
9/5/20255,487.55 KRW
9/4/20255,379.54 KRW
9/3/20255,253.53 KRW
9/2/20255,328.53 KRW
9/1/20255,331.53 KRW
8/29/20255,358.54 KRW
8/28/20255,328.53 KRW
8/27/20255,310.53 KRW
8/26/20255,340.53 KRW
8/25/20255,337.53 KRW
8/22/20255,346.53 KRW
8/21/20255,304.53 KRW
8/20/20255,274.53 KRW
8/19/20255,376.54 KRW
8/18/20255,511.55 KRW
8/14/20255,751.58 KRW
8/13/20255,826.58 KRW
8/12/20255,610.56 KRW
8/11/20255,643.56 KRW
8/8/20255,814.58 KRW
8/7/20255,529.55 KRW
8/6/20255,553.56 KRW
8/5/20255,538.55 KRW
Access this data via the Eulerpool API
Get Free API Key

NGeneBio Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
1.39 B KRW
-3.58 B KRW
-2.42 B KRW
Jan 1, 2019
1.48 B KRW
-4.35 B KRW
-6.86 B KRW
Jan 1, 2020
2.48 B KRW
-6.10 B KRW
-8.23 B KRW
Jan 1, 2021
7.16 B KRW
-8.56 B KRW
-8.43 B KRW
Jan 1, 2022
11.02 B KRW
-8.64 B KRW
-9.79 B KRW
Jan 1, 2023
4.35 B KRW
-13.52 B KRW
-12.77 B KRW
Jan 1, 2024
5.69 B KRW
-15.98 B KRW
-12.63 B KRW
Jan 1, 2025
21.24 B KRW
-8.28 B KRW
-5.54 B KRW

NGeneBio Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 4, 2026, 11:57 AM
 
REVENUEB KRW
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB KRW
EBITB KRW
EBIT MARGIN%
NET INCOMEB KRW
NET INCOME GROWTH%
SHARESM
20182019202020212022202320242025
1.391.482.487.1611.024.355.6921.24
–6.1167.84188.9553.80-60.5230.80273.27
46.4193.5763.6147.9149.1527.7089.3017.87
0.651.381.583.435.421.215.083.80
-3.58-4.35-6.10-8.56-8.64-13.52-15.98-8.28
-257.18-294.72-246.23-119.46-78.38-310.71-280.77-38.97
-2.42-6.86-8.23-8.43-9.79-12.77-12.63-5.54
–183.8719.862.4816.0630.49-1.10-56.11
16.0116.0116.0116.0116.0116.0116.0116.01
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales NGeneBio Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue NGeneBio Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare NGeneBio Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares NGeneBio Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against NGeneBio Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

NGeneBio Co stock margins

The NGeneBio Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of NGeneBio Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for NGeneBio Co.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
46.43 %
-257.24 %
-173.78 %
Jan 1, 2019
93.56 %
-294.63 %
-464.61 %
Jan 1, 2020
63.61 %
-246.20 %
-331.86 %
Jan 1, 2021
47.92 %
-119.46 %
-117.70 %
Jan 1, 2022
49.16 %
-78.38 %
-88.82 %
Jan 1, 2023
27.70 %
-310.67 %
-293.48 %
Jan 1, 2024
89.30 %
-280.75 %
-221.89 %
Jan 1, 2025
17.87 %
-38.97 %
-26.09 %

NGeneBio Co Stock Revenue, EBIT, Earnings per Share

The NGeneBio Co earnings per share therefore indicates how much revenue NGeneBio Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2019
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2020
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2021
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2022
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2023
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2024
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2025
0.00 KRW
0.00 KRW
0.00 KRW

NGeneBio Co business model & stock analysis

NGeneBio Co Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

NGeneBio Co historical P/E ratio, EBIT multiple, and P/S ratio

NGeneBio Co annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

NGeneBio Co shares outstanding

The number of shares of NGeneBio Co was 16.01 M in 2025. This indicates how many shares NGeneBio Co is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
16.01 M Stocks
Jan 1, 2019
16.01 M Stocks
Jan 1, 2020
16.01 M Stocks
Jan 1, 2021
16.01 M Stocks
Jan 1, 2022
16.01 M Stocks
Jan 1, 2023
16.01 M Stocks
Jan 1, 2024
16.01 M Stocks
Jan 1, 2025
16.01 M Stocks

NGeneBio Co stock splits

In NGeneBio Co's history, there have been no stock splits.
Price targets and forecasts for NGeneBio Co are not yet available.

NGeneBio Co shareholder structure

% Name
8.46062%
KT Corp
KT Corp
6.94014%
Hyun (Dong-bu)
Hyun (Dong-bu)
4.77480%
Choi (Dae Chul)
Choi (Dae Chul)
1.68222%
Hong (Chang Beom)
Hong (Chang Beom)
1.27726%
Kim (Gwang Jung)
Kim (Gwang Jung)
0.84606%
KT Investment
KT Investment

NGeneBio Co Executives and Management Board

16 members · avg. age 53 · 8 % women

Management

MK

Min Sik Kim (49)

Chief Executive Officer, Director · since 2025

–
GK

Mr. Gwang Jung Kim (51)

Vice President, Director

–
SY

Mr. Se Hyeok Yoon (46)

Managing Director

–
CH

Mr. Chang Beom Hong (47)

Managing Director

–
GH

Gye Seon Hong (47)

Internal Auditor

–
SY

Mr. Seong Wu Yang (45)

Assistant Managing Director

–

Board of Directors

MA

Myeong Gyu Ahn (50)

Director

–
DC

Mr. Dae Chul Choi (52)

Director · since 2025

–
GM

Gi Hun Moon (63)

Director

–
GS

Gi Hwan Song (62)

Director

–
YM

Mr. Yeong Ho Moon (61)

Other Non-Executive Director

–
EL

Ms. Eun Suk Lee (61)

Non-Executive Independent Director

–

Frequently asked questions about NGeneBio Co

Converted at the current exchange rate, the NGeneBio Co share trades at 0.98 EUR (1,620.00 KRW).

No history available for NGeneBio Co.

The revenue cannot currently be calculated for NGeneBio Co.

The profit cannot currently be calculated for NGeneBio Co.

The P/E ratio cannot be calculated for NGeneBio Co at the moment.

The P/S cannot be calculated for NGeneBio Co currently.

The Eulerpool Quality Score for NGeneBio Co is 3/10.

The ISIN of NGeneBio Co is KR7354200008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of NGeneBio Co is 354200.KQ. The ticker symbol is used to trade NGeneBio Co shares on the stock exchange.

NGeneBio Co paid dividends every year for the past 0 years.

NGeneBio Co is assigned to the 'Health' sector.

The dividends of NGeneBio Co are distributed in KRW.

All fundamentals and in-depth analysis of NGeneBio Co

Our stock analysis for NGeneBio Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of NGeneBio Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

NGeneBio Co Stock
NGeneBio Co Revenue→
NGeneBio Co Stock
NGeneBio Co Net Income→
NGeneBio Co Stock
NGeneBio Co P/E→
NGeneBio Co Stock
NGeneBio Co P/S→
NGeneBio Co Stock
NGeneBio Co EBIT→
NGeneBio Co Stock
NGeneBio Co Dividend→
NGeneBio Co Stock
NGeneBio Co Directors Dealings→
NGeneBio Co Stock
NGeneBio Co Stocks→
NGeneBio Co Stock
NGeneBio Co Market capitalization→
NGeneBio Co Stock
NGeneBio Co Debt→
NGeneBio Co Stock
NGeneBio Co Liabilities→
NGeneBio Co Stock
NGeneBio Co Equity→
NGeneBio Co Stock
NGeneBio Co AAQS→
NGeneBio Co Stock
NGeneBio Co Employees→
NGeneBio Co Stock
NGeneBio Co ROE→
NGeneBio Co Stock
NGeneBio Co ROA→
NGeneBio Co Stock
NGeneBio Co ROCE→
NGeneBio Co Stock
NGeneBio Co News→
NGeneBio Co Stock
NGeneBio Co Analyst Price Targets→

Health Stocks

Ngl Fine ChemNfl Biosciences SASNGS GroupNextleaf SolutionsNiagen BioscienceNextCureNibec CoNextCell PharmaNicoxNextBioMedical CoNidan Laboratories and HealthcareNexstim OyjAll Stocks A–Z →